HemAcure - The Project
HemAcure - The Project
HemAcure - The Project

HemAcure: Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe haemophilia A

The bleeding disease haemophilia A is caused by a genetic deficiency in clotting factor VIII (FVIII). At stage the therapies for treating haemophilia A mainly involve the application of recombinant factor VIII (rFVIII) which implies that patients need regular infusions with this factor. Thus, a permanent solution in the form of cell therapy is an extremely attractive approach for the treatment of this bleeding disease.
The innovative idea behind HemAcure: The isolation of endothelial cells from peripheral blood of haemophilia A patients and FVIII gene correction of those cells. The transduced cells will then be transplanted into the patient in a medical device designed for therapeutic cells (undefinedCell PouchTM). The cells in this kind of cell bag are connected with the bloodstream of the patient and shall allow a continuous release of FVIII into the patient’s blood. The overall aim of this new approach is to significantly improve the quality of life of haemophilia A patients and reduce the side effects of the disease.

 

The project is coordinated by the University Hospital of Würzburg (undefinedUKW) and started on November 1st, 2015. A total of about 5.6 million Euros has been awarded to the consortium by the European Union within Horizon 2020 to run the project over three years.

HemAcure Consortium

HemAcure Partners
Search
Home
Top

HemAcure on @twitter

News Section

HemAcure is proud to be example in Roland Berger article about Regenerative...

Read more

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

Social Media

Follow us on Twitter! @HemAcure_EU